Regulatory inspection

From Codex of clinical research

Regulatory inspection – is the process where regulatory authorities or agencies review and evaluate the conduct of clinical trials, research sites, sponsors, or contract research organizations (CROs) to ensure compliance with applicable regulations, guidelines, and standards.

These inspections are typically conducted by regulatory agencies such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in the European Union.

Definitions

ICH E6(R2)

1.29 Inspection:
The act by a regulatory authority(ies) of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authority(ies) to be related to the clinical trial and that may be located at the site of the trial, at the sponsor's and/or contract research organization’s (CRO’s) facilities, or at other establishments deemed appropriate by the regulatory authority(ies) [1].

Role of inspections

The purpose of regulatory inspections is to verify that:

Procedures of inspection

Regulatory inspections may be conducted on a routine basis as part of regulatory oversight or in response to specific concerns or complaints. Inspections may be announced or unannounced, and findings may result in regulatory actions, such as warnings, fines, or suspension of clinical trial activities.

See also

Another relevant pages

Links to this page

References

  1. ICH, 2016, Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2), https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf Accessed Sep 2023

External links